Daxas® is the first oral COPD-specific anti-inflammatory therapy for severe COPD patients on maintenance treatment with inhaled drugs who have:
- Symptoms of chronic cough and sputum
- A history of frequent exacerbations
A potent and specific inhibitor of the enzyme phosphodiesterase 4 (PDE4), Daxas® has a unique mode of action. When added to first-line maintenance treatment Daxas® provides incremental benefits such as significantly reduced exacerbations.1–3 This section provides a summary of the key information about Daxas®, including the additive benefits of Daxas® therapy, detailed evidence from pivotal clinical studies, and a list of frequently asked questions about Daxas®.
This section includes essential information about Daxas®, including a video explaining how Daxas® works at the molecular level, the additive benefits of Daxas® therapy, a profile of a typical COPD patient treated with Daxas®, and safety information.
Daxas® clinical studies
Learn more about the pivotal phase III Daxas® clinical studies, which confirmed that Daxas® reduced exacerbations when added to first-line maintenance treatment in patients with severe COPD, who had symptoms of chronic cough and sputum, moderate-to-severe airflow limitation, and a history of exacerbations.
Fifteen common questions about Daxas® are answered here, including ‘How is Daxas® different to other COPD treatments?’ and ‘Will patients feel better on Daxas®?’
- Calverley PMA, Rabe KF, Goehring U-M, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94.
- Fabbri LM, Calverley PMA, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703.
- Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011;163:53-67.